Keros Therapeutics (KROS) Common Equity (2019 - 2025)

Keros Therapeutics has reported Common Equity for 7 years, with the latest figure at $303.1 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 46.96% year-over-year to $303.1 million; the trailing twelve-month figure through Dec 2025 stood at $303.1 million (down 46.96% YoY), and the FY2025 full-year result was $303.1 million, down 46.96% from the prior year.
• Common Equity for Q4 2025 stood at $303.1 million, down from $703.6 million in the prior quarter.
• The five-year high for Common Equity was $728.9 million in Q1 2025, with the low at $211.2 million in Q2 2022.
• Historically, Common Equity has averaged $381.5 million across 5 years, with a median of $314.7 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity surged 1098.8% — and 2025, when it tumbled 46.96%.
• Keros Therapeutics' Common Equity stood at $243.2 million in 2021, then increased by 14.08% to $277.4 million in 2022, then advanced by 19.75% to $332.2 million in 2023, then jumped by 72.04% to $571.6 million in 2024, then slumped by 46.96% to $303.1 million in 2025.
• The last three Common Equity figures came in at $303.1 million (Q4 2025), $703.6 million (Q3 2025), and $706.7 million (Q2 2025), per Business Quant data.